Despite opposition from the Association of the British Pharmaceutical Industry (ABPI), the UK government has confirmed its plans to raise the revenue clawback rate paid by pharma for branded medicines under the statutory scheme by just over 3%, from 24.4% to 27.5% for 2023.
The UK government has published a report outlining progress on the Rare Disease Action Plan 2022, as well as details of the priorities of the Rare Disease Framework for 2023.
Marking the annual Rare Disease Day on 28 February, this article examines how developments in genomics and healthcare are leading to the diagnosis of many rare diseases and helping to pinpoint the care individual patients need.
